PortalPublikationenBelantamab mafodotin in combination with novel agents in rel...

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Standard

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. / Nooka, Ajay K; Weisel, Katja; van de Donk, Niels Wcj; Routledge, David; Otero, Paula Rodriguez; Song, Kevin; Quach, Hang; Callander, Natalie; Minnema, Monique C; Trudel, Suzanne; Jackson, Nicola A; Ahlers, Christoph M; Im, Ellie; Cheng, Shinta; Smith, L; Hareth, Nahi; Ferron-Brady, Geraldine; Brouch, Maria; de Oca, Rocio Montes; Paul, Sofia; Holkova, Beata; Gupta, Ira; Kremer, Brandon E; Richardson, Paul.

in: FUTURE ONCOL, Jahrgang 17, Nr. 16, 06.2021, S. 1987-2003.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nooka, AK, Weisel, K, van de Donk, NW, Routledge, D, Otero, PR, Song, K, Quach, H, Callander, N, Minnema, MC, Trudel, S, Jackson, NA, Ahlers, CM, Im, E, Cheng, S, Smith, L, Hareth, N, Ferron-Brady, G, Brouch, M, de Oca, RM, Paul, S, Holkova, B, Gupta, I, Kremer, BE & Richardson, P 2021, 'Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design', FUTURE ONCOL, Jg. 17, Nr. 16, S. 1987-2003. https://doi.org/10.2217/fon-2020-1269

APA

Nooka, A. K., Weisel, K., van de Donk, N. W., Routledge, D., Otero, P. R., Song, K., Quach, H., Callander, N., Minnema, M. C., Trudel, S., Jackson, N. A., Ahlers, C. M., Im, E., Cheng, S., Smith, L., Hareth, N., Ferron-Brady, G., Brouch, M., de Oca, R. M., ... Richardson, P. (2021). Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. FUTURE ONCOL, 17(16), 1987-2003. https://doi.org/10.2217/fon-2020-1269

Vancouver

Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K et al. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. FUTURE ONCOL. 2021 Jun;17(16):1987-2003. https://doi.org/10.2217/fon-2020-1269

Bibtex

@article{62dcba6b8b1a49c8a1d4b5f73988099d,
title = "Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design",
abstract = "Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).",
author = "Nooka, {Ajay K} and Katja Weisel and {van de Donk}, {Niels Wcj} and David Routledge and Otero, {Paula Rodriguez} and Kevin Song and Hang Quach and Natalie Callander and Minnema, {Monique C} and Suzanne Trudel and Jackson, {Nicola A} and Ahlers, {Christoph M} and Ellie Im and Shinta Cheng and L Smith and Nahi Hareth and Geraldine Ferron-Brady and Maria Brouch and {de Oca}, {Rocio Montes} and Sofia Paul and Beata Holkova and Ira Gupta and Kremer, {Brandon E} and Paul Richardson",
year = "2021",
month = jun,
doi = "10.2217/fon-2020-1269",
language = "English",
volume = "17",
pages = "1987--2003",
journal = "FUTURE ONCOL",
issn = "1479-6694",
publisher = "Future Medicine Ltd",
number = "16",

}

RIS

TY - JOUR

T1 - Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

AU - Nooka, Ajay K

AU - Weisel, Katja

AU - van de Donk, Niels Wcj

AU - Routledge, David

AU - Otero, Paula Rodriguez

AU - Song, Kevin

AU - Quach, Hang

AU - Callander, Natalie

AU - Minnema, Monique C

AU - Trudel, Suzanne

AU - Jackson, Nicola A

AU - Ahlers, Christoph M

AU - Im, Ellie

AU - Cheng, Shinta

AU - Smith, L

AU - Hareth, Nahi

AU - Ferron-Brady, Geraldine

AU - Brouch, Maria

AU - de Oca, Rocio Montes

AU - Paul, Sofia

AU - Holkova, Beata

AU - Gupta, Ira

AU - Kremer, Brandon E

AU - Richardson, Paul

PY - 2021/6

Y1 - 2021/6

N2 - Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).

AB - Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).

U2 - 10.2217/fon-2020-1269

DO - 10.2217/fon-2020-1269

M3 - SCORING: Journal article

C2 - 33682447

VL - 17

SP - 1987

EP - 2003

JO - FUTURE ONCOL

JF - FUTURE ONCOL

SN - 1479-6694

IS - 16

ER -